The UK International Coronavirus Network (UK-ICN) aims to enhance knowledge of the virus family to prepare responses for future outbreaks.
List view / Grid view
Regs & Legs
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
Laboratories operating under GMP or GLP regulations must follow guidelines set by agencies to protect scientific integrity or demonstrate quality assurance of manufactured products.
Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
MEPs have requested that the EU adopts new plans to phase out the use of animals in scientific research and testing, focusing on alternatives instead.
Evaluation of neurotoxicity effects is an active area of investigation in drug discovery and disease modeling.
The cell painting assay uses up to six fluorescent dyes to label and visualize a variety of subcellular structures at the single cell level.
Dr Robert Hewitt explains why the need of biospecimen brokers to protect their commercially-sensitive information can result in significant issues for industry end-users and the results of their research.
Examining existing R&D processes with a consolidated approach enables the stop of disjointed workflows to engage on the digitisation journey.
A National Science and Technology Council and Office for Science and Technology Strategy will be established to aid the UK's scientific industry.
The WHO and Swiss Confederation are set to launch a BioHub Facility, intended to facilitate the sharing of pathogens globally.
Dmytro Spilka explains why UK biotech companies are receiving increasing levels of investment and why this trend is likely to continue.
The UK Government will invest £29.3 million to test the effectiveness of COVID-19 vaccines against variants in 3,000 blood samples a week.